State of Oklahoma
SoonerCare
Lymphir™ (denileukin diftitox-cxdl) Prior Authorization Form

Member Name:_____ Date of Birth:_____ Member ID#:_____

Drug Information

Physician billing (HCPCS code:_____) Start Date (or date of next dose):_____

Dose:_____ Regimen:_____

Billing Provider Information

Provider NPI:_____ Provider Name:_____

Provider Phone:_____ Provider Fax:_____

Prescriber Information

Prescriber NPI:_____ Prescriber Name:_____

Prescriber Phone:_____ Prescriber Fax:_____ Specialty:_____

Criteria

For Initial Authorization:

1. Please indicate the diagnosis and information:
   - ☐ **Cutaneous T-Cell Lymphoma**
     - A. Is diagnosis relapsed or refractory stage I-III cutaneous T-cell lymphoma? Yes ☐ No ☐
     - B. Is there expression of CD25 on ≥20% of malignant cells by immunohistochemistry? Yes ☐ No ☐
     - C. Has the member received at least 1 prior systemic therapy? Yes ☐ No ☐
   - ☐ **If diagnosis is not listed above, please indicate diagnosis**: _____

Additional Information: _____

_____

For Continued Authorization:

1. Date of last dose:_____
2. Does member have any evidence of progressive disease while on denileukin diftitox-cxdl?
   Yes ☐ No ☐
3. Has the member experienced adverse drug reactions related to denileukin diftitox-cxdl therapy?
   Yes ☐ No ☐

*If yes, please specify adverse reactions:*_____

_____

Prescriber Signature:_____ Date:_____

I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge. *Failure to complete this form in full will result in processing delays.*

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:	CONFIDENTIALITY NOTICE
University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4	*This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.*